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History
It was in 1984 that the ﬁrst algorithm for warfarin
doses was announced in the UK byWilson and James,
two haematologists at the Hillingdon Hospital in
Middlesex.1 They developed the idea that the necess-
ary dose of anticoagulation had a direct mathematical
correlation with the international normalised ratio
(INR) blood test for each patient. As part of their study
they also showed that the maintenance of anticoagu-
lation by traditional means was laborious and costly,
and that the results achieved were often indiﬀerent,
while those produced by the computer were at least as
good as those achieved usingmanual systems.Medical
and secretarial time was saved by the use of such a
system, in which a reports and audit facility also
ensured that statistics about the clinic and its eﬃcacy
were readily available.
At the time of the publication of the Hillingdon
algorithm in the British Medical Journal, two authors
(RTJ and MS) were junior hospital doctors. Both made
use of the paper algorithm in their clinical practice,
but it was to be more than ten years before they
transferred the idea to the program which became
INRstar.
Background
Warfarin is useful for a number of diﬀerent clinical
conditions which require the clotting ability of the
blood to be reduced. Among the most common clin-
ical indications is atrial ﬁbrillation, a type of irregular
pulse which is linked with an increased risk of stroke,
as small clots generated in the heart by the irregularity
ﬁnd their way to the brain, where they become lodged
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in the narrowed circulation, causing partial or com-
plete blockage of the blood supply to that part of the
brain.
Use of warfarin in these and other conditions can
signiﬁcantly reduce themorbidity andmortality of the
condition itself, but there are also disadvantages to its
use. There is no standard dose which may be given to
similar patients with the same condition, as each indi-
vidual responds diﬀerently to the same dose. This is
why patients onwarfarin require regular blood tests to
monitor their INR – the ratio between their blood
clotting time with and without warfarin. According to
each INR result their warfarin dose can be adjusted
and the date of their next test arranged accordingly.
However, each clinical condition requires the INR to
be maintained within diﬀerent ranges. The ideal situ-
ation for both patient and clinician is where the INR
remains fairly constant for a given dose of warfarin,
with the minimal number of tests in a given period of
time.
Warfarin dosing has been performed manually in
both primary and secondary care for many years, but
the evidence suggests that it has not been done very
well in either setting.2,3 Over the past ten years there
has been agradual shift in clinical care fromsecondary to
primary care for many conditions and treatments,
including anticoagulation. Extra funding is sometimes,
but not always, made available to support this new
responsibility.4 There is now strong evidence to sup-
port the idea that anticoagulation can reduce the risk
of thrombotic stroke in those patients with uncom-
plicated atrial ﬁbrillation by up to 90%. This evidence
has resulted in a substantial increase in the number of
patients taking warfarin on a long-term basis.5
The net result has been that primary care has had to
cope with a dramatically increased workload to help
prevent a condition with signiﬁcant morbidity, in an
area of clinical medicine where historical evidence sug-
gests poor performance, and with little if any add-
itional funding being made available.6,7
Software development
The ﬁrst version of INRstar was initially developed in
Cornwall in the early 1990s by one of the authors (MS)
in collaboration with a Visual Basic programmer based
in the USA. When it was evident that the product had
commercial possibilities, the other two authors (RTJ
and DB) became part of the team to handle marketing
and technical issues respectively. Despite the limit-
ations of the early version, which ran on a stand-alone
Windows PC, it gained early acceptance across the
county in Cornwall, where funding was made avail-
able to install it in every practice.
Then began a steady process of development and
reﬁnement, to incorporate all the key elements of
national guidance from organisations such as the British
Society for Haematology and the British Committee
for Standards in Haematology, which dictated stan-
dard target INR values and durations of treatment for
each clinical condition.8 As the software becamemore
widely used, practices produced their own wish-lists
for advanced functionality, including the requirement
to network the software across a whole practice, and to
integrate it within their clinical systems. The rate of
change in software development proved to be so far
ahead of its time that when the criteria were published
for enhanced services under the terms of the New GMS
Contract, no additional development was necessary
for INRstar, as it already met all the national standards,
which included:1,9
. Maintenance of a register of patients onwarfarin. With
INRstar, practices canmaintain an up-to-date register
of all anticoagulation monitoring services delivered
to patients, indicating patient name; date of birth;
the indication for, and length of, treatment; includ-
ing the target INR.
. Call and recall. INRstar includes integral func-
tionality to ensure that systematic call and recall of
patients on the anticoagulation register is taking
place.
. Individual management plan. INRstar includes all
the necessary information to prepare an individual
management plan for each patient, giving the diag-
nosis, planned duration and therapeutic range to be
obtained.
. Record keeping. INRstar includes the functionality
to help maintain records of the performance and
outcomes of the service provided, including adverse
events such as bleeding episodes requiring hospital
admission and deaths caused by anticoagulants.
. Clinical audit. INRstar includes the most compre-
hensive set of audit reports of any software in this
market, allowing clinical audit of the care of patients,
including untoward incidents. This allows a review
of the success of the practice in maintaining its
patients within the designated INR range as part of
quality assurance.
Current functionality
INRstar now comes in two versions: the classic general
practice (GP) network application is currently in use
at more than 500 practices in the UK, Ireland, Australia
and New Zealand; the new web browser version opens
the door for entire trusts to host an area-wide man-
agement system on their own servers, crossing the
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boundaries between primary and secondary care. This
new version also raises the possibility of individual
patients logging in and calculating doses when they are
geographically remote from their own clinician.
Clinicians log into INRstar from their own work-
station and are presented with a splash screen (see
Figure 1) to remind them that the software can only
provide guidance, and that overall responsibility for
clinical decisions rests with the clinician, who may be
aware of factors that will skew the algorithm in an
unpredictable fashion.
Because of the comprehensive training and edu-
cation arranged by Sullivan Cuﬀ Software for new
users of INRstar, clinicians do not generally treat the
computer suggestions as dogma. Should an adverse
event occur, they are reassured by the £3 million of
indemnity insurancewhich the company has arranged
to cover such an eventuality.
Each clinician then logs into the system with their
own username and passwordwhich is linked to a read-
only audit trail. In this way all individual actions by users
logged into the system can be decrypted for medico-
legal purposes should the situation arise.
Patients are added to INRstar through the main
registration module, either by copying the demo-
graphic details by hand, or by importing the details
automatically from the GP clinical system. This func-
tionality is currently available for iSoft Synergy and
System 6000, and it is expected that before long this
degree of integrationwill also be available for the other
leading GP clinical systems.10
The registration screen includes a list of diagnoses,
each with its own target INR range based on the current
recommendations from the British Society for Haema-
tology (see Figure 2). The system is ﬂexible enough to
add new diagnoses or customise INR ranges for indi-
vidual patients where necessary. Entering the patient’s
most recent INR test and the current review interval
allows the program to forecast the right dose and
follow-up period until the next test is due.
Flexibility to suit diﬀerent patients and working
practices is one of the key aspects of INRstar, so options
are available when adding a new patient to give clin-
icians the chance to choose how to manage that indi-
vidual. For instance, patients may be dosed either in
traditional milligrams or in multiples of same-strength
warfarin tablets to avoid possible confusion between
diﬀerent strengths and colours. Warfarin control may
be further improved by allowing half-tablets in dose
regimes; this option may be switched oﬀ for those
patients who lack the necessary manual dexterity (see
Figure 3).
Users also have the option to choose between the
original Hillingdon algorithm to manage their patients,
or the more recently developed Warwick algorithm,
which appears to control INR levels with greater ac-
curacy and is now regarded as the gold standard.
The main monitoring screen (see Figure 4) allows
users to enter INR results into the program to allow
the software to make suggestions before the patient’s
dosage schedule is automatically printed oﬀ. How-
ever, a computer cannot be dogmatic in this context –
it can only make suggestions, which is why INRstar
includes the option for the clinician to override the
software if they consider that other factors such as
concurrent medication or dietary changes might mean
that the computer suggestions are inappropriate for
the time being.
The algorithm determines the next review interval,
so that stable patients are asked to return at longer
intervals, up to a maximum of ten weeks. Even the
most stable patient will still require four or ﬁve tests a
year, while less stable patients will be asked to return at
more frequent intervals.
Once the INR result and dosing suggestions have
been saved to the system, a dosage chart can then be
Figure 1 Thewelcome screen in INRstar reminds each user that the software can only provide some guidance
for the clinician
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printed out for the patient to take away as an aide-
me´moire until their next test is due. The whole process
conforms very well with the idea of a one-stop clinic
when combined with the use of near-patient testing
(NPT) to measure the INR, and inmost user practices
thewhole clinic is run on a day-to-day basis by a suitably
trained extended-role nurse.
There will, however, be occasions when the person
in charge of the clinic needs further advice by referring
patients to a supervising clinician, who may be on site
or geographically distant. In either case, the referral can be
done electronically from within INRstar, allowing the
supervisor to check the results and make further adjust-
ments as necessary, without interrupting theworkﬂow
of the clinic nurse, who can remain within the treat-
ment room throughout the process.
Clinical system integration
As alreadymentioned, full integrationwithGP clinical
systems is the next major development for INRstar.
That integration has already been achieved for iSoft
Synergy and System 6000, and further work is cur-
rently in progress to allow integration with EMIS and
In Practice Systems.10–12
Figure2 Default values for target INR for each clinical conditionare those recommendedby theBritish Society
for Haematology
Figure 3 The dosing parameters are ﬂexible enough to suit diﬀerent patient and practice requirements
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The integration model means that INR values added to
the clinical system will automatically be copied and
pasted into INRstar, which will then perform its usual
calculations before copying the dose schedule back
into the clinical system. New warfarin patients can
automatically be generated from the clinical system
into INRstar at the touch of a button, without the need
to copy registration details across by hand.
Reports and audits
INRstar includes a comprehensive reporting suite
for clinical audit purposes. The available functionality
includes options for examining the degree of control
of individual patients and groups of patients, as well
as the entire database. In the web browser version of
INRstar, the system supervisor can compare ﬁgures
across the diﬀerent organisations within their juris-
diction.
The available options include point prevalence (PP)
calculation, the gold standard method of comparing
diﬀerent methods of anticoagulation management
(see Figure 5). After the switch to INRstar, all practices
show a steady increase in their point prevalence scores,
and anational feedback schemeco-ordinatedbySullivan
Cuﬀ Software allows practices to compare themselves
with other users across the country every quarter. The
mean value PP for users of INRstar is currently 80%+
with occasional users achieving a perfect score of
100% (see Figure 6).
Education and training
It has long been recognised that the setting up of
anticoagulation clinics in primary care requires many
resources other than the necessary software, and with
its background in postgraduate medical education,
Sullivan Cuﬀ Software makes a number of resources
available to its new and existing users.
All hospital and primary care trusts that now form
the customer base are oﬀered comprehensive training
and education in the use of the software and its inte-
gration within the context of a clinical setting. The
company website provides useful material for prac-
tices taking on this role, including summaries of the
evidence base for the use of computerised decision
support software; links to many of the main academic
papers on the subject; and manuals describing the
processes that should be considered when setting up
an anticoagulation clinic.13
Beneﬁts to primary care
The ways in which practices and their patients have
been shown to beneﬁt from the use of INRstar can be
summarised as follows:
. improved anticoagulation control
. reduced number of INR tests required to maintain
good control
. improved patient safety
. reduced potential for errors in dosing
. improved patient convenience
. contribution to practice ﬁnancial income.
Figure 4 The monitoring screen for each patient includes all recent data available in a single view
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Figure 5 Point prevalence data is generated within seconds and provides a useful measure of the degree of
warfarin control
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Figure 6 Anonymised data is fed back to each user site so that practices can compare their performance with
other members of the INRstar community
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